MIRM250117P20000
- 0.00
- 0.000.00%
Mirum Pharmaceuticals Newsroom
Insider Sale: CHIEF MEDICAL OFFICER of $MIRM (MIRM) Sells 6,969 Shares
Mirum Pharmaceuticals Insider Sold Shares Worth $319,598, According to a Recent SEC Filing
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $60
Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Support Buy Rating
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Mirum Pharmaceuticals Sees FY24 Revenue $336M, Consensus $332.78M
Mirum Pharmaceuticals Surpasses 2024 Sales Guidance
Mirum Pharma Expects to Initiate Phase 2 Study for MRM-3379 in Fragile X Syndrome in 2025 >MIRM
Mirum Pharma FDA PDUFA Date for Chenodiol in Cerebrotendinous Xanthomatosis Is March 28, 2025 >MIRM
Mirum Pharma: Volixibat VISTAS Study in Primary Sclerosing Cholangitis Expected to Complete Enrollment 2H 2025
Mirum Pharmaceuticals Sees 2025 Product Sales $420M-$435M >MIRM
Mirum Pharmaceuticals Sees 2025 Positive Cash Flow From Ops >MIRM
Express News | Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing
Insider Sale: PRESIDENT AND COO of $MIRM (MIRM) Sells 1,998 Shares
Investors in Mirum Pharmaceuticals (NASDAQ:MIRM) Have Seen Solid Returns of 175% Over the Past Three Years
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)